{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(3)"],"submitter":["Gude MF"],"pubmed_abstract":["<h4>Objective</h4>Physiologically, pregnancy-associated plasma protein-A (PAPP-A) serves to liberate bound IGF1 by enzymatic cleavage of IGF-binding proteins (IGFBPs), IGFBP4 in particular. Clinically, PAPP-A has been linked to cardiovascular disease (CVD). Stanniocalcin-2 (STC2) is a natural inhibitor of PAPP-A enzymatic activity, but its association with CVD is unsettled. Therefore, we examined associations between the STC2-PAPP-A-IGFBP4-IGF1 axis and all-cause mortality and CVD in patients with type 2 diabetes (T2D).<h4>Design</h4>We followed 1284 participants with T2D from the ADDITION trial for 5 years.<h4>Methods</h4>Circulating concentrations of STC2, PAPP-A, total and intact IGFBP4 and IGF1 and -2 were measured at inclusion. End-points were all-cause mortality and a composite CVD e"],"journal":["Endocrine connections"],"pagination":["e220451"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9986395"],"repository":["biostudies-literature"],"pubmed_title":["The STC2-PAPP-A-IGFBP4-IGF1 axis and its associations to mortality and CVD in T2D."],"pmcid":["PMC9986395"],"pubmed_authors":["Bjerre M","Hjortebjerg R","Sandbæk A","Charles MH","Gude MF","Witte DR","Frystyk J"],"additional_accession":[]},"is_claimable":false,"name":"The STC2-PAPP-A-IGFBP4-IGF1 axis and its associations to mortality and CVD in T2D.","description":"<h4>Objective</h4>Physiologically, pregnancy-associated plasma protein-A (PAPP-A) serves to liberate bound IGF1 by enzymatic cleavage of IGF-binding proteins (IGFBPs), IGFBP4 in particular. Clinically, PAPP-A has been linked to cardiovascular disease (CVD). Stanniocalcin-2 (STC2) is a natural inhibitor of PAPP-A enzymatic activity, but its association with CVD is unsettled. Therefore, we examined associations between the STC2-PAPP-A-IGFBP4-IGF1 axis and all-cause mortality and CVD in patients with type 2 diabetes (T2D).<h4>Design</h4>We followed 1284 participants with T2D from the ADDITION trial for 5 years.<h4>Methods</h4>Circulating concentrations of STC2, PAPP-A, total and intact IGFBP4 and IGF1 and -2 were measured at inclusion. End-points were all-cause mortality and a composite CVD e","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-21T19:51:13.189Z","creation":"2025-02-18T23:26:15.906Z"},"accession":"S-EPMC9986395","cross_references":{"pubmed":["36607154"],"doi":["10.1530/EC-22-0451"]}}